Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.
2.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J.

J Clin Oncol. 2005 Nov 1;23(31):7811-9.

PMID:
16258083
3.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N.

N Engl J Med. 2005 Oct 20;353(16):1673-84.

4.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ.

J Clin Oncol. 2008 Mar 10;26(8):1231-8. doi: 10.1200/JCO.2007.13.5467. Epub 2008 Feb 4.

5.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

6.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N.

J Clin Oncol. 2012 Nov 1;30(31):3792-9. doi: 10.1200/JCO.2011.40.0010. Epub 2012 Sep 17.

7.

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Telli ML, Hunt SA, Carlson RW, Guardino AE.

J Clin Oncol. 2007 Aug 10;25(23):3525-33. Review.

PMID:
17687157
8.

Adjuvant trastuzumab therapy for HER2-positive breast cancer.

Jahanzeb M.

Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: 10.3816/CBC.2008.n.037. Review.

PMID:
18757259
9.

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.

Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS.

J Clin Oncol. 2004 Sep 15;22(18):3700-4. Erratum in: J Clin Oncol. 2005 Mar 1;23(7):1594.

PMID:
15365066
10.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N.

J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.

11.

Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA.

Clin Breast Cancer. 2006 Aug;7(3):237-43.

PMID:
16942640
12.

Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer.

Ishihara M, Mukai H, Nagai S, Mukohara T.

Int J Clin Oncol. 2009 Oct;14(5):431-5. doi: 10.1007/s10147-009-0898-z. Epub 2009 Oct 25.

PMID:
19856052
13.

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.

Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA.

J Clin Oncol. 2016 Feb 20;34(6):581-7. doi: 10.1200/JCO.2015.61.8413. Epub 2015 Sep 21.

14.

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.

Sawaki M, Mukai H, Tokudome N, Nakayama T, Taira N, Mizuno T, Yamamoto Y, Horio A, Watanabe T, Uemura Y, Ohashi Y.

Breast Cancer. 2012 Jul;19(3):253-8. doi: 10.1007/s12282-011-0270-9. Epub 2011 Apr 28.

PMID:
21526424
15.

Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.

Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, Downey A, Vogel CL, Chia S, Muggia F.

Clin Breast Cancer. 2007 Aug;7(9):690-6.

PMID:
17919349
16.

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C.

J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733.

PMID:
18323546
17.

Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.

Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys H, Cocquyt V.

Acta Clin Belg. 2010 Sep-Oct;65(5):300-4.

PMID:
21128555
18.

High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.

Paluch-Shimon S, Wolf I, Goldberg H, Evron E, Papa MZ, Shabtai M, Barsuk D, Yosepovich A, Modiano T, Catane R, Kaufman B.

Acta Oncol. 2008;47(8):1564-9. doi: 10.1080/02841860802060844.

PMID:
18607846
19.

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl HG, Lichinitser M, Manikhas AG, Coumbos A, Kreienberg R, du Bois A, Harbeck N, Jackisch C, Müller V, Pauschinger M, Thomssen C, Lehle M, Catalani O, Lück HJ.

J Clin Oncol. 2010 Mar 20;28(9):1473-80. doi: 10.1200/JCO.2009.21.9709. Epub 2010 Feb 22.

PMID:
20177030
20.

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ.

J Clin Oncol. 2007 Sep 1;25(25):3859-65. Epub 2007 Jul 23.

PMID:
17646669

Supplemental Content

Support Center